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BMS-204352
1 , chemically designated as (3S)-(ϩ)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one) ( Fig. 1) , is a maxi-K channel opener . This compound has potential to prevent and treat ischemic stroke. Stroke is a major cause of death and long-term disability, affecting more than 700,000 people in the US annually (Williams et al., 1999) . Acute ischemic stroke is the most common form, producing pathologically fatal levels of intracellular calcium (Ca 2ϩ ) in neurons at risk. Maxi-K channels are large-conductance voltage-and Ca 2ϩ -activated K ϩ channel proteins (Chang et al., 1997) . The fluoro-oxyindole BMS-204352 is a potent maxi-K channel opener and provides significant levels of cortical neuroprotection in rat models of stroke by augmenting an endogenous mechanism for regulating Ca 2ϩ entry and membrane potential to protect the neurons (Cheney et al., 2001; Gribkoff et al., 2001) .
Positron emission tomography imaging showed that F-18-labeled BMS-204352 is rapidly and widely distributed in rats; the brain uptake was rapid and occurred at high levels (Kiesewetter et al., 2002) . The compound had a brain/plasma exposure ratio of 9:1 following an intravenous bolus dose of 5 mg/kg in rats . BMS-204352 was 99.5% protein bound in rat serum (Krishna et al., 2001) . Following an intraarterial infusion or oral dose of [ 14 C]BMS-204352 (6 mg/kg) (Krishna et al., 2002) , the elimination of total radioactivity in plasma was very slow compared with that of the parent compound. Radioactivity was primarily excreted in the feces (more than 85% of administered dose over a 7-day collection period). The comparable recoveries of the radioactive dose in urine (5.9% for intraarterial and 4.5% for oral dose) suggested that the oral absorption of BMS-204352 was nearly complete. However, the absolute oral bioavailability of BMS-204352 was 55% in rats. Collectively, these data suggested that a C-14-derived radioactive material in plasma had a much longer t 1/2 than the parent compound and that the compound exhibited the first-pass metabolism in rats.
Within 1 h following i.v. dosing of [ 14 C]BMS-204352 to rats, more than 85% of the radioactivity in plasma was found to be unextractable by organic solvents. In this study, we characterized the covalently bound radioactive material by acid hydrolysis of rat plasma proteins, HPLC isolation, analysis by LC/MS and NMR, and organic synthesis of a metabolite analog. We also propose a P450-catalyzed bioactivation mechanism for the covalent binding through a novel orthoquinone methide intermediate.
Materials and Methods

Materials. [
14 C]BMS-204352 (radiochemical purity 99.5%) was synthesized at Bristol-Myers Squibb (Princeton, NJ) (Dischino et al., 2003) . desFluoro BMS-204352 lysine adduct (BMS-349821, 98% pure) was synthesized as described below. The structure of BMS-204352 is shown in Fig. 1 . Am-monium acetate and polyethylene glycol-300 were purchased from Aldrich Chemical Co. (Milwaukee, WI) . Sodium hydroxide, hydrochloric acid (36.5-38%), sodium phosphate (dibasic), silica gel TLC plates (250 nm), and silica gel were purchased from EM Scientific (Gibbstown, NJ) . N-␣-Boc-L-lysine methyl ester was obtained from Bachem Biosciences (King of Prussia, PA). P450 inhibitors and pooled microsomes were purchased from BD Gentest (Woburn, MA). Ecolite liquid scintillation cocktail was purchased from ICN Biomedicals, Inc. (Costa Mesa, CA). For solid phase extraction, Oasis HLB C 18 cartridge columns (1 and 10 ml) were obtained from Waters Corporation (Milford, MA). Acetonitrile-d 3 (D 99.8%) and DMSO-d 6 were obtained from Cambridge Isotope Laboratories, Inc. (Andover, MA). All other chemicals used were of reagent grade or better.
Synthesis of des-Fluoro BMS-204352 Lysine Adduct BMS-349821. BMS-225113, a chloro-analog of BMS-204352, was synthesized as described previously (Kiesewetter et al., 2002) and used as the stating material. desFluoro BMS-204352 lysine adduct was synthesized in three steps as shown in Fig. 2 and described below.
des-Fluoro BMS-204352 Boc-L-lysine methyl ester. To a solution of BMS-225113 (221.3 mg, 0.59 mmol) dissolved in CH 3 CN (3 ml) was added N-␣-Boc-L-lysine methyl ester (274.3 mg, 0.61 mmol) in CH 3 CN (2 ml) followed by addition of solid K 2 CO 3 (197.8 mg, 1.41 mmol). After the reaction was stirred at 90°C under a blanket of argon for 1 h, TLC (ethyl acetate/ hexanes 3:7) showed the starting material BMS-225113 was consumed. The reaction was cooled to room temperature, filtered, and the solid washed with 2 ϫ 2 ml CH 3 CN. The filtrate was evaporated under vacuum to afford 380.5 mg (yield 108%) of crude solid, which was used without further purification. TLC (ethyl acetate/hexanes 3:7): one spot at R f 0.1 by UV.
des-Fluoro BMS-204352 Boc-L-lysine adduct. To a solution of the above methyl ester (370 mg) dissolved in tetrahydrofuran (5 ml) was added 1 M LiOH (2.5 ml, 2.5 mmol). The resulting solution was stirred under argon at 60°C. After 1 h, TLC (CHCl 3 /MeOH/HOAc 8:2:0.1) showed the starting ester was consumed. The reaction was cooled to room temperature, and CH 2 Cl 2 (20 ml) was added. The solution was extracted with 2 M HCl (10 ml), 2 ϫ 10 ml H 2 O, and brine (10 ml). The organic phase was dried over MgSO 4 , filtered and evaporated under vacuum to afford 331.2 mg (yield 96%) of the product. TLC (CHCl 3 /MeOH/HOAc, 8:2:0.1): one spot at R f 0.6 by UV. MS: 586.2 (M ϩ H) ϩ ; 584.2 (M Ϫ H) Ϫ . des-Fluoro BMS-204352 Lysine Adduct (BMS-349821). A solution of the Boc-protected adduct (331.2 mg, 0.57 mmol) was dissolved in trifluoroacetic acid (5 ml) and stirred at room temperature. After 1 h, TLC (CHCl 3 /MeOH/ HOAc, 8:2:0.1) showed disappearance of the starting material. The solvent was evaporated under a stream of nitrogen. The resulting residue was evaporated twice from CHCl 3 /MeOH (9:1) (10 ml), and dried under high vaccuum to afford 385.5 mg (96%, trifluoroacetic acid salt) of a foam. The crude product was chromatographed on silica (30 g) eluting with CHCl 3 /MeOH/HOAc (74:25:1). Fractions containing the desired product were combined and evaporated under vacuum to afford 252.8 mg of a residue. This residue was dissolved in MeOH (5 ml), boiled with activated carbon (200 mg), and filtered through a bed of celite. The celite was washed with MeOH (30 ml), and the combined filtrate was evaporated under vacuum to afford a glass-like material. This solid was evaporated from Et 2 O (10 ml) to afford 233. 10AT ; Shimadzu, Kyoto, Japan), an autoinjector (SIL 10AD), and a diode array detector (SPD-M10A). A Zorbax RX C 18 column (4.6 mm ϫ 250 mm, 5 m) equipped with a guard column was used. All HPLC analyses were performed by enclosing the column in an Eppendorf CH-30 column heater maintained at 35°C. The mobile phase flow rate was 1 ml/min. The retention time of the parent compound was confirmed before each run by radioactivity or UV detection. A gradient of two solvent systems, A and B, was used. Solvent A was water containing 15 mM ammonium acetate, pH 4.3. Solvent B consisted of acetonitrile/solvent A (95:5, v/v). Solvent B was started at 25% and then increased in a linear manner as follows: 50% (35 min), 80% (40 min), and then maintained at 80% for 2 min before it was decreased to 25% in 3 min.
Radioactivity Detection. Radioactivity in biological samples was determined by mixing aliquots of the samples with 15 ml of Ecolite cocktail and counting with a Packard Tri-Carb 2250 liquid scintillation analyzer (PerkinElmer Life Sciences, Boston, MA). An on-line ␤-Ram radioactivity detector (0.5-ml liquid cell; IN/US Systems Inc., Tampa, FL) was also used for HPLC radioactivity profiling. In addition, HPLC effluent was collected at 25-s intervals after sample injection into 96-deep-well Lumaplates with a Gilson model 202 fraction collector (Gilson Medical Electronics, Middleton, WI). The effluent in the plates was dried with a Speed-Vac (Savant Instruments, Holbrook, NY), and the plates were counted for 10 min per well with a TopCount scintillation analyzer (PerkinElmer Life Sciences) (Zhu et al., 2000) .
LC/MS Analysis. LC/MS analysis was performed on a Finnigan LCQ mass spectrometer with an electrospray ionization source Thermo Finnigan MAT (San Jose, CA). Samples were analyzed in the negative ion mode. Half of the HPLC eluent was directed to the Finnigan LCQ mass spectrometer through a divert valve set to divert the flow to waste from 0 to 10 min. From 10 min until the end of the HPLC run, the eluent flow was directed to the mass spectrometer. The capillary temperature used for analysis was between 220 and 230°C. The nitrogen gas flow rate, spray current, and voltages were adjusted to give maximum sensitivity. The other half of the HPLC eluent was directed to either the on-line detector or a fraction collector. The collision energy was 20 to 35%.
Exact mass measurements of the parent and product ions were obtained on a Micromass Q-TOF Ultima mass spectrometer that was equipped with lockspray under positive ion mode. The m/z 556.2771 and 278.1141 of an infused 20 ng/l leucine enkephalin solution were used as lock masses. The Q-Tof was tuned to 18,000 resolution at half peak height using an insulin tuning solution. The experimentally obtained masses of product ions (326.0199 and 147.1138 Da) agreed to their respective calculated values with an error less than 1 mDa.
NMR. NMR experiments were performed on a Bruker 600 system (Newark, DE) equipped with a 3-mm probe and operating at 599.87 MHz. 1D 1 H, 2D correlation spectroscopy (proton-proton coupling), 2D 1 H-13 C heteronuclear multiple quantum coherence spectroscopy and heteronuclear multiple-bond correlation spectroscopy (long range nuclear coupling, and bond-bond coupling), 13 0.25, 1, 4, 8, 24, 72 , and 168 h) were obtained from three rats for each time point. For isolation of a large quantity of the metabolite, plasma was collected from nine rats 6 h after single 5 mg/kg intravenous doses of [ 14 C]BMS-204352 (9.5 Ci/mg). Plasma samples were prepared in tubes containing EDTA and centrifugation (10 min, 1300g at 4°C).
Extraction of Radioactivity from Plasma. Pooled plasma samples (0.2 ml) were mixed with 1 ml of methanol. After vortexing, the protein precipitates were pelleted by centrifugation at 3500 rpm in an IEC Centra-7R refrigerated centrifuge (IEC, Needham Heights, MA) or 15 min at 10°C. Similarly, separate portions of plasma were extracted with methanol after mixing with potassium hydroxide, potassium carbonate, and urea at 0.1, 0.5, and 6 M, respectively. Portions (0.2 ml) of the plasma samples were also extracted with 0.5-ml size C 18 cartridges, which were eluted with 1 ml of methanol, 2 ml of water, and then 1 ml of methanol. Control plasma samples were made by spiking [ 14 C]BMS-204352 in rat plasma (equivalent to the radioactivity level in rat plasma) and extracted with methanol or C 18 cartridges. The control plasma samples were also incubated at 37°C for 0, 1, 3, and 5 h before extraction. Extraction with methanol, acetonitrile, or ethyl acetate was repeated four times.
Electrophoresis of Radioactivity in Plasma Proteins. Proteins from 0.25-to 72-h plasma were precipitated with methanol and washed twice with methanol. Portions of the plasma proteins (0.3 mg) were dissolved by boiling in 20 l of an electrophoresis sample buffer containing (w/v) 4% SDS, 20% glycerol, 10% ␤-mercaptoethanol, and 0.1% bromophenol blue in 125 mM Tris buffer (pH 6.0) and loaded on a 10% polyacrylamide stacking gel. The gel was run for 70 min at 160 V on a Bio-Rad Mini-Protean II system (Bio-Rad, Hercules, CA), stained with Comassie blue R solution for 1 h, and destained in water/methanol/acetic acid (65:25:10, v/v/v) for 3 h. After drying onto a piece of filter paper, the gel was scanned for 24 h on a Packard Electronic Autoradiography, Instantimager.
Dialysis of Radioactivity in Plasma Proteins.
A portion of the methanolprecipitated and washed 1-h plasma proteins (30 mg) was dissolved in 2 ml of 4 M urea. Control plasma was spiked with an equivalent level of [ 14 C]BMS-204352 and dissolved in 4 M urea. The plasma protein and control samples were dialyzed in membrane tubes with a molecular mass cutoff of 3,500 Da. The membrane tubes were purchased from American Scientific Products (McGaw Park, IL). The samples were dialyzed in 1 liter of 35 mM phosphate buffer containing 4 M urea, pH 7.4, for 24 h followed by additional 40 h in an additional 2 liters of buffer. Aliquots of samples from the dialysis bags were taken for determination of radioactivity.
Acid Hydrolysis of Rat Plasma Proteins for Metabolite Isolation. Plasma was pooled from nine rats 6 h after a single 5 mg/kg intravenous dose of [
14 C]BMS-204352 (9.5 Ci/mg). The 6-h time point was selected to obtain maximal concentrations of protein bound radioactivity. A 28-ml plasma sample was extracted with 60 ml of methanol and washed twice with 60 ml of methanol. The protein pellet was dissolved in 31 ml of 6 M HCl. The mixture was incubated in a 110°C oil bath for 24 h in a sealed tube. Potassium phosphate was added to the hydrolysate to a final concentration of 200 mM and the pH of the solution was adjusted to 5.0 with 12 M NaOH. The solution was passed through four 1-ml C 18 cartridges. The radioactive material was eluted with methanol and concentrated under a stream of nitrogen. The concentrated sample was separated by HPLC on a semipreparative Zorbax C 18 , 9.4 ϫ 250 mm 5 column (10 injections). The effluent was collected as fractions. A 50 l portion of each fraction was counted for radioactivity. The fractions that corresponded to the major radioactive peak were pooled and repurified on a Supelco ABZϩ, 4.6 ϫ 250 mm column (6 injections). For the semipreparative Zorbax column, solvent B was held at 1% for 2 min, increased to 99% over 31 min, then held at 99% for 5 min at 4 ml/min. For the Supelco ABZ column, solvent B was held at 30% for 2 min and then increased to 50% over 20 min at 1 ml/min. The isolated sample was analyzed by MS and NMR. Pooled (1, 4, 12 h) plasma was extracted by addition of 4 ml of acetonitrile to 2 ml of plasma, vortexed for 1 min, and centrifuged at 3000 rpm for 10 min. The extraction was repeated three times. The protein residues were dried under a nitrogen stream in a 15-ml pyrex tube. HCl (6 N, 8 ml) was added to the protein pellet. The solution was refluxed for 24 h at 110°C. Two separate hydrolysis controls were incubations of [
14 C]BMS-204352 (50 g, 9.5 Ci/ mg) and BMS-349821 (1 mg, the des-fluoro lysine adduct) under similar conditions with 6 N HCl in the presence of proteins from 6 ml of control plasma. The hydrolysate was neutralized by adding a 6 N NaOH solution containing 1 M sodium phosphate to adjust to pH 7.5 and passed through a 10 cc C 18 cartridge. The radioactive material was eluted with methanol and concentrated under a stream of nitrogen. The residue was redissolved in 250 l of 70% acetonitrile in 15 mM ammonium acetate and centrifuged at 3000 rpm for 10 min before injecting onto the HPLC column. The radioactive fractions were pooled, evaporated, dissolved in 70% acetonitrile, and analyzed by LCQ with negative electrospray ionization.
In Vitro Experiments. The cofactor requirements, the influence of GSH, and the effect of P450 inhibitors on covalent binding were evaluated using human liver microsomes. [
14 C]BMS-204352 (25 M) was incubated with microsomal proteins (2 mg/ml), NADPH (1.25 mM), and bovine serum albumin (8 mg/ml) in 0.5 ml of 60 mM phosphate buffer, pH 7.4. The incubations were done in 15-ml glass test tubes at 37°C in a shaking water bath. Each assay was started by addition of the microsomes followed by incubation for 2 to 5 h at 37°C. A control incubation without NADPH was done with each set of experiments. In some experiments, GSH (5 mM) was also included in the incubation mixtures for attenuating covalent binding activity. In the inhibition experiments, inhibitors (2.5-5 l, dissolved in methanol or acetonitrile) were added to 0.5 ml of incubation mixtures containing 1.4 mg of microsomal proteins and 25 M [ 14 C]BMS-204352 in 60 mM phosphate buffer, pH 7.4. Suicide inhibitors furafylline, orphenadrine, troleadomycin, and 1-aminobenzotrazole were preincubated with microsomes in the presence of NADPH for 10 min before the substrate was added. The reactions were initiated by adding the substrate, continued for 60 min at 37°C, and terminated by protein precipitation with methanol. After centrifugation, the protein pellet was saved, thoroughly washed with methanol, acetonitrile, or ethyl acetate for three times, digested with 1 M KOH for 24 h, and neutralized with 1M HCl, and analyzed for radioactivity by scintillation counting.
Results
Covalent Binding of Radioactivity to Rat Plasma Proteins. Table 1 shows the concentration of radioactivity in plasma samples taken at different times after dosing with [
14 C]BMS-204352 and the percentages of radioactivity extracted from these plasma samples under various conditions. After protein precipitation and extensive wash of the protein pellet with methanol, the extractable radioactivity was 69.1 and 32.8% of original radioactivity in the plasma samples at 0.2 and 1 h, respectively, and approximately 10% or less after 1 h. Methanol extraction under basic conditions (0.1 M potassium hydroxide for time point at 1 h or 0.5 M potassium carbonate for the time point at 72 h) and after denaturation (6 M urea) did not improve the percentages of extractable radioactivity. Protein precipitation by 10% trichloroacetic acid also gave less than 10% of the radioactivity in the supernatant (4-h plasma sample). In addition, solid phase extraction on C 18 cartridges gave low percentages of extractable radioactivity. Based on plasma volumes of about 8 ml for rats (Davies and Morris, 1993) , the percentage of the radioactive dose covalently bound to plasma proteins was calculated to be about 5.8% at 4 h after i.v. dosing in rats. In contrast to these ex vivo samples, however, control rat plasma incubated with [
14 C]BMS-204352 gave quantitative recovery of radioactivity from extraction by methanol. The spiked plasma samples showed high percentages (87-99%) of extractable radioactivity even after incubation for up to 5 h at 37°C. Figure 3 shows an image of the radioactivity bound to plasma proteins of rats dosed with [
14 C]BMS-204352 after the proteins were separated on an SDS-polyacrylamide gel by an electric field. About 80% of the radioactivity comigrated with albumin at 68 kDa and 20% comigrated with other protein components. Figure 4 shows the results of dialysis of unextractable radioactivity in plasma proteins from rats dosed with [
14 C]BMS-204352. In this experiment, substances with molecular mass of less than 3,500 Da would diffuse out of the dialysis membrane bag. After 24 and 64 h dialysis, respectively, 93 and 95% of the radioactivity in methanolwashed plasma proteins remained inside the dialysis bags, compared with 42 and 12% of the radioactivity for spiked rat plasma proteins.
Isolation and Structural Confirmation of des-Fluoro Des-OMethyl BMS-204352 Lysine Adduct.
From the acid hydrolysis, 83.5% of the radioactivity in plasma proteins was recovered after initial C 18 cartridge clean-up. HPLC analysis showed that more than 90% of the radioactivity was eluted in one radioactive peak. After a two-step purification procedure, about 24 g of this major radioactive component was isolated from acid hydrolysis of plasma proteins from the nine rats dosed with [
C]BMS-204352. LC/MS/MS analysis showed that this isolate contained a single compound with a molecular ion at [M Ϫ 1]
Ϫ of 470 (in negative mode). MS/MS analysis gave a major fragmentation ion at m/z 324, suggesting neutral loss of lysine OD showed six aromatic protons. In DMSO, the isolate showed a broad peak (1H) at 5.3 ppm (a ␣-methine proton of an amino acid). Two-dimensional (correlation spectroscopy) 1 H NMR supported a lysine structure. Proton signals were observed at 2.0 (2H), 2.1 (2H), 3.2 (2H), and 5.3 ppm (1H) in the region of 2.0 to 5.5 ppm. The couplings between protons at 3.2 ppm (a CH 2 next to amine nitrogen) and at 2.1 ppm (a CH 2 in the chain), between protons at 2.1 and 2.0 ppm, and between protons at 2.0 ppm and at 5.3 ppm (a ␣-methine proton) were observed. The isolate had max values at 220, 250, and 293 nm in its UV spectrum, similar to those of the parent drug. Fluorine NMR of the isolate showed loss of the fluorine from the ring carbon (Ϫ160 ppm to Ϫ180 ppm versus CFCl 3 ) but retention of the three fluorine atoms in the trifluoromethyl group (Ϫ83 ppm and Ϫ70 ppm versus CFCl 3 ) of BMS-204352. Based on these MS, 1 H, and 19 F NMR results, the 24-h acid hydrolysis product of the BMS-204352-rat plasma protein adduct was identified as the lysine conjugate of desfluoro des-O-methyl BMS-204352. 14 C] BMS-204352 produced a single prominent radioactive peak 2 at 21.5 min (Fig. 6,  bottom panel) . No other significant radioactive peaks were observed from the acid hydrolysis of rat plasma protein. LC/MS analysis showed that this peak 2 at 21.5 min also had a molecular ion at m/z 470 and a prominent MS 2 fragment ion at m/z 324, suggesting a common structure to the minor acid hydrolysis product of BMS-349821. Based on the retention time, LC/MS properties, and the NMR data of rat plasma isolate, the peak 2 was identified as des-fluoro des-O-methyl BMS-204352 lysine adduct.
P4503A-Mediated Protein Covalent Binding in Vitro. Table 2 shows protein bound (unextractable) radioactivity from incubations of [ 14 C]BMS-204352 with human liver microsomes in the presence and absence of NADPH. Radioactivity covalently bound to proteins in microsomal incubations was determined by extensive extractions with methanol and acetonitrile of unbound label from microsomal incubations followed by scintillation counting of residual C-14. The percentage of unextractable radioactivity in the incubation mixtures increased 14-fold (2 h) to 25-fold (5 h) compared with incubations run for the same period without NADPH. GSH only attenuated the protein covalent binding by about 30%. Table 3 shows the effect of various P450 inhibitors on protein covalent binding of radioactivity for in vitro incubations of [
14 C]BMS-204352 with human liver microsomes. Aminobenzotriazole, a nonselective P450 suicide inhibitor, reduced binding to near background levels. Selective inhibitors of P450 isozymes 1A2, 2A6, 2C19, 2C9, 2D6 slightly inhibited the protein covalent binding. Although 2B6 inhibitor orphenadrine and 2E1 inhibitor 4-methylpyrazole caused significant inhibitions, the isozyme 3A inhibitors, ketoconazole and troleadomycin, almost completely inhibited protein covalent binding. In summary, the covalent binding of radioactivity in vitro required NADPH and was selectively inhibited by P4503A inhibitors, suggesting a bioactivation mechanism by P4503A. A mechanism for covalent binding of BMS-204352 is proposed in Fig. 7 .
Discussion
Analysis of the plasma from rats dosed with [ 14 C]BMS-204352 showed that the majority of the radioactivity in the samples remains with the protein after extraction with organic solvents, electrophoresis, or dialysis under denaturing conditions. On the other hand, radioactivity in control rat plasma incubated with [ 14 C]BMS-204352 was readily separated from the protein by these same procedures. These results show that BMS-204352 is activated in rats to a metabolite that binds covalently to plasma proteins. The in vitro results showed that protein covalent binding is NADPH-dependent and selectively prevented by P4503A inhibitors. Therefore, it is likely that metabolic activation of BMS-204352 in vivo is mediated by cytochrome P4503A isozyme(s).
Since the structure of the BMS-204352 covalently bound protein adduct could not be determined directly, the covalently bound protein sample was treated with acid to hydrolyze the amino acid backbone to its component amino acids. The hydrolysis product was identified as a lysine conjugate of des-fluoro des-O-methyl BMS-204352. Hence, the BMS-204352-protein adduct simply represents the net replacement of the ring fluorine atom of des-O-methyl BMS-204352 with the ⑀-amino group of a lysine residue. Although BMS-204352 was hydrolyzed to the des-O-methyl product (des-fluoro des-O-methyl hydroxy BMS-204352), the O-demethylation in the protein adduct (desfluoro des-O-methyl BMS-204352 lysine adduct) was not likely caused during acid hydrolysis. The reason is that only Ͻ5% of synthetic des-fluoro BMS-204352 lysine adduct was O-demethylated to des-fluoro des-O-methyl BMS-204352 lysine adduct under the same acid hydrolysis conditions. Therefore, the O-demethylation probably proceeded the adduct formation between lysine residue and an activated BMS-204352 species. A proposed mechanism for the metabolic activation of BMS-204352 is shown in Fig. 7 to account for The samples (containing 30 mg of protein) were dialyzed in 1 liter of buffer for 24 h and in another 2 liters of buffer for an additional 40 h before the radioactivity in the dialysis bag was measured.
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at ASPET Journals on April 19, 2017 dmd.aspetjournals.org these observations. In this mechanism, BMS-204352, a 3-(2-methoxyphenyl)-3-fluoro-2-oxindole, is oxidized by P4503A to lead to Odemethylation. A nonenzymatic elimination of hydrogen fluoride from the formed phenol leads to formation of the ortho-quinone methide metabolite. The resulting electrophilic reactive metabolite undergoes a nonenzymatic Michael addition reaction with the ⑀-amino group of lysine residue(s) in proteins to form a covalently bound adduct.
There are two unusual aspects regarding to the above proposed mechanism involving the ortho-quinone methide covalently bound to plasma protein (mostly albumin) through a lysine adduct. First, the ortho-quinone methide reactive intermediate generated by P4503A in rat livers or microsomal incubation was apparently stable enough to escape from the enzyme active site and covalently bound to albumin molecules being processed at endoplasmic reticulum membranes. Second, the hard nucleophile, ⑀-amino group of lysine residue(s) and not the soft nucleophile, the sulfhydryl group of cysteine residue(s) involved in the adduct formation. Quinone methides are electrophilic reactive intermediates with positive charge density centered mainly at the exocyclic methylene carbon (Turner, 1964) . Both the formation and the rate/type of subsequent nucleophilic additions of para-quinone methides of alkylated phenols can be affected by delocalization of the positive charge density through extended -conjugation at the exocyclic methylene carbon or through hydrogen binding interactions at the carbonyl and spatial interactions (Filar and Winstein, 1960; Bolton et al., 1992) . Extended -conjugation at the para-position of 4-alkylcatechols enhanced the rates of isomerization of an ortho-quinone to para-quinone methide through increasing the stability of quinone methides (Iverson et al., 1995) . Eugenol paraquinone methides were stabilized dramatically by extended -conjugation . The electrophilic reactivity of paraquinone methide of butylated hydroxytoluene increased as increased stabilization through hydrogen binding interactions with solvents (Bolton et al., 1992) . The relative stability of the ortho-quinone methide in this study might be due to the extended conjugation to an aromatic ring system and a carbonyl group at the nucleophilic attack site. Our preliminary results indicated that BMS-204352 was also a time-dependent inactivator of P4503A in microsomal incubations (data will be published separately). It is also important to point out that treating BMS-204352 with BCl 3 led to formation of an uncharacterized black polymer material, indicating that the phenol precursor formed in tetrahydrofuran or methylene chloride was not stable and polymerized. The sulfhydryl group in cysteine or glutathione was the common nucleophile to form adducts with para-quinone methides or imine methides Nakagawa et al., 1983; Tajima et al., 1983; Nocerini et al., 1985; Thompson et al., 1990 ). Bolton and colleagues used amino acid and peptide models to study influence of para-quinone methide reactivity on the alkylation of thiol and amino groups in protein . Their results indicated that peptide alkylation should occur in the order of cysteine thiol Ͼ N-terminal amino Ͼ N-⑀-lysine based on chemical reactivity. Actually, para-quinone methide from 2-tert-utyl-4,6-dimethylphenol was at least 10-fold more reactive to form adduct with cysteine than with ⑀-amino group of lysine (McCracken et al., 1997) . However, the para-quinone methide alkylated hemoglobin (containing no cysteine residues) mainly at N⑀-lysine, suggesting that other factors such as the relative concentrations of competing nucleophilic groups and their accessibility determined by protein secondary and tertiary structures might be also important for protein covalent binding . In addition, solvolysis rates of the para-quinone methide by the hard nucleophile, water, increased as increased stabilization of the methide positive charge through hydrogen binding interactions (Bolton et al., 1992) . Rat albumin contains 32 cysteine residues and 52 lysine residues (Peters and Reed, 1980) . However, the ortho-quinone methide in this study formed adducts exclusively with lysine, which might be explained by the relative stability of this extended methide. GSH only modestly attenuated the protein covalent binding, further demonstrating the strong preference of the hard nucleophile, ⑀-amino group over the soft nucleophile, sulfhydryl group for adduct formation. There might be specific binding or motifs in proteins directing the ortho-quinone methide to a lysine-containing pocket of plasma proteins before the nucleophilic addition occurs to form the lysine adduct. Overall, the stabilization of the ortho-quinone methide through extended conjugation would make the reactive intermediate possible to escape from the active site of P450 enzyme(s) and to react with the hard nucleophile, ⑀-amino group of lysine residue(s) in proteins.
para-Alkylated phenol such as butyl hydroxytoluene and eugenol, and 3-methylindole undergo oxidation through a direct abstraction of a hydrogen atom from the exocyclic methylene group , Thompson et al., 1990 Skiles and Yost, 1996) . Safrole [1-allyl-3,4-(methylenedioxy)-benzene] undergoes O-demethylation to catechol (1-allyl-3,4-dihydroxybenzene), which can be oxidized to an ortho-quinone followed by isomerization to form a para-quinone methide (Bolton et al., 1994) . Tamoxifen undergoes the following two steps of P450 oxidation: para-hydroxylation on one benzene ring or O-demethylation at a different ring to generate para-alkylated phenols followed by P450-mediated proton abstraction to form the paraquinone methides (Dehal and Kupfer, 1999; Fan and Bolton, 2001) . In this study, we identified a novel ortho-quinone methide, which was formed by a P450-mediated O-demethylation followed by a nonenzymatic elimination of HF. Another ortho-quinone methide was formed through a quinone reduction to ortho-alkylated phenol followed by a distal elimination of cyanide in the quinone anticancer antibiotics saframycins A and C, which rapidly led to an intramolecular ring close to form a hydroxyquinone immonium ion (Lown et al., 1982) . Other examples of reactive electrophilic metabolites that covalently bind to proteins include ortho-quinone from catechols (Dehal and Kupfer, 1999) , epoxides (Sahali-Sahly et al., 1996; Yamamoto et al., 2002) , iminoquinone (Shen et al., 1999; Lai et al., 2000) , and acylglucuronides (Bolze et al., 2002) . The lysine residue in protein can form covalent binding with carbonyl groups through Schiff base formation (Braun et al., 1995) , with ␣,␤-unsaturated ketones through Michael addition reactions (Szweda et al., 1993) , or with epoxides through nucleophilic substitution reactions (Sujatha et al., 2001) . BMS-204352 lysine adduct identified in this study represents another example for the lysine residue forming a covalent bond through nucleophilic addition reaction.
There are reversible-and irreversible-types of protein covalent binding. Covalent binding through disulfide bonds of cysteine residues of proteins with sulfhydryl-containing drugs such as captopril and omapatrilat are reversible-type covalent binding (Ramaswamy et al., 2001) . The drug material(s) can be released from the covalent bound adduct(s) through replacement by free thiols in glutathione or cysteine. Covalent binding through nucleophilic addition reactions of amino acids such as cysteine or lysine residues represent irreversible-type covalent binding. Their further metabolism may depend on the metabolism of targeted proteins. It is noteworthy that the half-life of radioactivity in rat plasma following [ 14 C]BMS-204352 is similar to that of albumin in plasma [i.e., 48 h (Reed et al., 1988) ].
Protein covalent binding may lead to such consequences as the production of autoantibodies, inflammation, and cancer. Some of these reactive metabolites are related to hepatic toxicities (Pumford and Halmes, 1997) . The formation of methide reactive intermediates a The proteins were precipitated with methanol, and the protein pellet was washed extensively with methanol, ethyl acetate, and acetonitrile before analysis for radioactivity.
b The percentage of radioactivity in protein pellets was calculated based on the total radioactivity of 1,250,000 dpm used in the incubations. a Radioactivity unextractable with methanol. Incubation without NADPH gave 744 dpm (mean of three trials).
b The inhibitors were preincubated with microsomes and NADPH for 10 min before addition of ͓ 14 C͔BMS-204352.
at ASPET Journals on April 19, 2017 dmd.aspetjournals.org has been linked to hepatotoxicity, pulmonary toxicity, carcinogenicity, and tumor promotion (Yost, 1989; Thompson et al., 2001; Monks and Jones, 2002) . Protein covalent binding has been observed with drugs that are generally considered safe (captopril, aspirin, valproic acid), as well as drugs that have been associated with hepatic impairment (acetaminophen overdose) and idiosyncratic or allergic reactions (diflunisal and zomepirac) (Uetrecht, 1992; Pumford and Halmes, 1997) . Although the biological consequences of this P450 activation pathway of BMS-204352 are unknown, no toxicological findings directly attributable to its protein covalent binding have been observed with the compound in rats. In summary, within an hour of dosing rats with 
